1、 1.Constant currencies(cc),core results and free cash flow are non-IFRS measures.An explanation of non-IFRS measures can be found on page 44 of the Condensed Financial Report.Unless otherwise noted,all growth rates in this Release refer to same period in prior year.2.Please see detailed guidance ass

2、umptions on page 6.3.USD millions unless indicated otherwise.Novartis International AG CH-4002 Basel Switzerland https:/ https:/ FINANCIAL RESULTS|FINANZERGEBNISSE Novartis delivered high single-digit sales growth,achieved 40%core margin and further advanced the pipeline in 2025 Ad hoc announcement

3、pursuant to Art.53 LR Full year Net sales grew+8%(cc1,+8%USD)with core operating income1 up+14%(cc,+12%USD)o Sales growth driven by continued strong performance from priority brands including Kisqali(+57%cc),Kesimpta(+36%cc),Pluvicto(+42%cc),Scemblix(+85%cc)and Cosentyx(+8%cc)o Core operating income

4、 margin1 was 40.1%,+210 basis points(cc)Operating income grew+25%(cc,+21%USD);net income up+19%(cc,+17%USD)Core EPS1 grew+17%(cc,+15%USD)to USD 8.98 Free cash flow1 of USD 17.6 billion(+8%USD)driven by higher net cash flows from operating activities Fourth quarter Net sales-1%(cc,+1%USD),impacted by

5、 US generic erosion and revenue deduction adjustments;core operating income+1%(cc,+1%USD)o Priority brands continued their strong momentum including Kisqali(+44%cc),Kesimpta(+27%cc),Pluvicto(+70%cc),Scemblix(+87%cc)and Cosentyx(+11%cc)Q4 selected innovation milestones:o Remibrutinib FDA submission f

6、or the most common subtype of CINDU o Pelabresib positive Phase III MANIFEST-2 96-week data;filing planned in EU,US Phase III planned o Itvisma FDA approval as the only gene replacement therapy for a broad SMA population o Scemblix EC approval for newly diagnosed patients with Ph+CML in chronic phas